FDA Warns Oft-Quoted Dermatologist For Promoting Investigational Drug

摘要

FDA's recent warning letter to prominent dermatologist Leslie Baumann for her remarks promoting a not-yet-approved Botox alternative makes a statement early in the year about the rigor the agency is bringing to its public safety mission.Head of the Baumann Cosmetic & Research Institute in Miami Beach, Fla., and a former professor of dermatology at the University of Miami, Baumann notes in a Feb. 1 blog post that she has "for decades worked at the forefront of dermatology research and drug trials."